# US 2003/0224012 A1 · Polynucleotides and polypeptides BASB033 from Neisseria meningitidis and their uses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0224012 A1
- Document ID: US20030224012A1
- Status: Published application
- Kind: A1
- Application number: 10/417,885
- Filed: 2003-04-17
- Published: 2003-12-04
- Earliest claimed: 1998-09-14
- Assignees: SmithKline Beecham Biologicals s.a.
- Inventors: Jean-Louis Ruelle
- Web page: https://patentgrep.com/patent/US20030224012A1

## CPC

- G01N 33/56911: {Bacteria}
- A61P 31/04: Antibacterial agents
- C07K 14/22: from Neisseriaceae (F)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 2039/51: {comprising whole cells, viruses or DNA/RNA}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The DNA of the invention are characterised in that they concern the whole or part of genes, with their reading frame, to be found in Neisseria meningitidis, but not in Neisseria gonorrhoeae, or in Neisseria lactamica except the genes involved in the biosynthesis of the polysaccharide capsule, frpA, frpC, opc, porA, rotamase the sequence IC1106, IgA protease, pilline, pilC, trunsierin binding proteins and opacity proteins. The invention also concerns the polypeptides corresponding to these DNA and the antibodies directed against these polypeptides. It is applicable in the prevention and the detection of meningococcus induced infections and meningitis.

## Claims

### Claim 1

An isolated polypeptide comprising an amino acid sequence which has at least 85% identity to the amino acid sequence selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:4.

### Claim 2 (depends on 1)

An isolated polypeptide as claimed in claim 1 in which the amino acid sequence has at least 95% identity to the amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4.

### Claim 3 (depends on 1)

The polypeptide as claimed in claim 1 comprising the amino acid sequence selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:4.

### Claim 4

An isolated polypeptide of SEQ ID NO:2, SEQ ID NO:4.

### Claim 5 (depends on 1, 2, 3, 4)

An immunogenic fragment of the polypeptide as claimed in any one of claims 1 to 4 in which the immunogenic activity of said immunogenic fragment is substantially the same as the polypeptide of SEQ ID NO:2 SEQ ID NO:4.

### Claim 6

An isolated polynucleotide comprising a nucleotide sequence encoding a polypeptide that has at least 85% identity to the amino acid sequence of SEQ ID NO:2, 4 over the entire length of SEQ ID NO:2, 4 respectively; or a nucleotide sequence complementary to said isolated polynucleotide.

### Claim 7

An isolated polynucleotide comprising a nucleotide sequence that has at least 85% identity to a nucleotide sequence encoding a polypeptide of SEQ ID NO:2, 4 over the entire coding region; or a nucleotide sequence complementary to said isolated polynucleotide.

### Claim 8

An isolated polynucleotide which comprises a nucleotide sequence which has at least 85% identity to that of SEQ ID NO:1, 3 over the entire length of SEQ ID NO:1, 3 respectively; or a nucleotide sequence complementary to said isolated polynucleotide.

### Claim 9 (depends on 6, 7, 8)

The isolated polynucleotide as claimed in any one of claims 6 to 8 in which the identity is at least 95% to SEQ ID NO:1, 3.

### Claim 10

An isolated polynucleotide comprising a nucleotide sequence encoding the polypeptide of SEQ ID NO:2, SEQ ID NO:4.

### Claim 11

An isolated polynucleotide comprising the polynucleotide of SEQ ID NO:1, SEQ ID NO:3.

### Claim 12

An isolated polynucleotide comprising a nucleotide sequence encoding the polypeptide of SEQ ID NO:2, SEQ ID NO:4 obtainable by screening an appropriate library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO:1, SEQ ID NO:3 or a fragment thereof.

### Claim 13 (depends on 6, 7, 8, 9, 10, 11, 12)

An expression vector or a recombinant live microorganism comprising an isolated polynucleotide according to any one of claims 6-12.

### Claim 14 (depends on 13)

A host cell comprising the expression vector of claim 13 or a subcellular fraction or a membrane of said host cell expressing an isolated polypeptide comprising an amino acid sequence that has at least 85% identity to the amino acid sequence selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:4.

### Claim 15 (depends on 14)

A process for producing a polypeptide comprising an amino acid sequence that has at least 85% identity to the amino acid sequence selected from the group consisting of SEQ ID NO:2. SEQ ID NO:4 comprising culturing a host cell of claim 14 under conditions sufficient for the production of said polypeptide and recovering the polypeptide from the culture medium.

### Claim 16 (depends on 6, 7, 8, 9, 10, 11, 12)

A process for expressing a polynucleotide of any one of claims 6-12 comprising transforming a host cell with the expression vector comprising at least one of said polynucleotides and culturing said host cell under conditions sufficient for expression of any one of said polynucleotides.

### Claim 17 (depends on 1, 2, 3, 4, 5)

A vaccine composition comprising an effective amount of the polypeptide of any one of claims 1 to 5 and a pharmaceutically acceptable carrier.

### Claim 18 (depends on 6, 7, 8, 9, 10, 11, 12)

A vaccine composition comprising an effective amount of the polynucleotide of any one of claims 6 to 12 and a pharmaceutically effective carrier.

### Claim 19 (depends on 17, 18)

The vaccine composition according to either one of claims 17 or 18 wherein said composition comprises at least one other Neisseria meningitidis antigen.

### Claim 20 (depends on 1, 2, 3, 4, 5)

An antibody immunospecific for the polypeptide or immunological fragment as claimed in any one of claims 1 to 5.

### Claim 21 (depends on 1, 2, 3, 4, 5)

A method of diagnosing a Neisseria meningitidis infection, comprising identifying a polypeptide as claimed in any one of claims 1-5, or an antibody that is immunospecific for said polypeptide, present within a biological sample from an animal suspected of having such an infection.

### Claim 22 (depends on 1, 2, 3, 4, 5)

Use of a composition comprising an immunologically effective amount of a polypeptide as claimed in any one of claims 1-5 in the preparation of a medicament for use in generating an immune response in an animal.

### Claim 23 (depends on 6, 7, 8, 9, 10, 11, 12)

Use of a composition comprising an immunologically effective amount of a polynucleotide as claimed in any one of claims 6-12 in the preparation of a medicament for use in generating an immune response in an animal.

### Claim 24 (depends on 1, 2, 3, 4, 5)

A therapeutic composition useful in treating humans with Neisseria meningitidisdisease comprising at least one antibody directed against the polypeptide of claims 1-5 and a suitable pharmaceutical carrier.
